AlzGenomics Unveils Circular RNA Platform at ASGCT... Presents Data on Delivery to Splenic Immune Cells

Research Achievements in Circular RNA Delivery and Production Technologies

Demonstrating the Potential for Expanding Anti-Cancer Gene Therapy Platforms

AlzGenomics announced on May 15 that it presented its research achievements on next-generation RNA platforms at the American Society of Gene & Cell Therapy (ASGCT 2026), held in Boston, USA, from the 11th to the 15th.

A representative from Algenomics is presenting research achievements on the next-generation RNA platform at the American Society of Gene & Cell Therapy (ASGCT 2026), held in Boston, USA, from the 11th to the 15th. Algenomics

At this conference, AlzGenomics conducted one oral presentation and two poster presentations related to its circular RNA-based platform.

During the oral presentation, the company revealed research results showing that circular RNA can be selectively delivered to splenic immune cells using a polymer-based nano-carrier. According to the company, the delivery efficiency was three times higher and the expression duration was twice as long compared to linear RNA. This research was conducted jointly with Inha University. AlzGenomics explained that this technology has the potential to be utilized in the development of in vivo CAR-T therapy, which generates CAR-T cells directly within the body.

The poster presentations introduced a structural engineering technology that improves the productivity of long circular RNA. The company stated that it has doubled the production efficiency of circular RNA longer than 8kb compared to previous methods. Circular RNA has a limitation in that production efficiency decreases as the length increases.

Another presentation disclosed preclinical research results on 'RZ-002', an anti-cancer gene therapy platform targeting brain cancer. This approach simultaneously expresses anti-cancer genes and immune checkpoint inhibitors in cancer cells, seeking to reduce both the systemic side effects of conventional immuno-oncology drugs and the limitations posed by the blood-brain barrier through localized expression.

Lee Sungwook, CEO of AlzGenomics, stated, "Through ASGCT, we shared the competitiveness and scalability of AlzGenomics' platform technologies with researchers around the world," adding, "During the conference, we had in-depth discussions with multiple potential partners regarding possible collaborations."

This content was produced with the assistance of AI translation services.